Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Vertex Pharmaceuticals has reported total revenues of $73.66m for the first quarter ended 31 March 2011, compared to $22.42m for the same period in 2010.
Subscribe to our email newsletter
The company posted net loss of $176.1m, or $0.87 loss per diluted share, compared to $165.27m, or $0.83 loss per diluted share, for the same period last year.
For the first quarter of 2011, Vertex Pharma’s loss from operations was $159.9m, compared to 160.28m, for the same period in the prior year.
Vertex Pharma chairman, president and CEO Matthew Emmens said their progress in recent months with both INCIVEK for people with hepatitis C and VX-770 for people with cystic fibrosis marks a significant step toward Vertex becoming a company capable of discovering, developing and launching innovative new medicines for serious diseases.